Wednesday, January, 19, 2022 11:12:56
Trending News:
Fulcrum bags global rights for GSK's failed trial drug Losmapimod
Lilly & Avidity ink new licensing & research collaboration agreement
Alembic Pharma receives FDA approval for Teriflunomide tablets
Roche Pharma introduces Hemophilia A treatment drug in India
Category: Biotechnology
Vedanta Biosciences raises $27M for microbiome-derived products
Ojaswita Kutepatil December 24, 2018
The $27 million were raised in a Series-C financing with investors like Bristol-Myers Squibb and Bill & Melinda Gates Foundation participating in the round. The money would be utilized to advance the company's microbiome-derived product candidates. Vedanta Biosciences, Inc. (Vedanta), a renowned PureTech Health affiliate, …
Biotech firm Relay Therapeutics raises $400m in new capital funding
Relay Therapeutics, a privately-held biotechnology company based in Cambridge, Massachusetts, is currently in the news for securing $400 million in venture capital financing during a Series C funding round. The Series C funding, led by SoftBank Vision Fund, was participated in by new investors including …
Voluntis & AbbVie team up to develop companion digital therapeutics
Voluntis, a company specializing in digital therapeutics, has reportedly announced that it has formed a collaboration with research-based global biopharmaceutical company AbbVie, in order to improve patient care coordination in immunology through innovative digital therapeutic software. As per trusted sources, the companies will collectively leverage …
Aduro Biotech & Lilly to collaborate for R&D of novel immunotherapies
The U.S.-based global pharmaceutical firm Eli Lilly & Company, and California-based immunotherapy company, Aduro Biotech, are currently in the news for announcing a research collaboration, as well as an exclusive license deal, for the cGAS-STING pathway inhibitor program that would develop new immunotherapies for inflammatory …
Kineta, Pfizer sign million-dollar agreement to develop cancer therapy
Biotech firm Kineta has recently announced an agreement with pharmaceutical corporation Pfizer, which includes an upfront payment of $15 million and possibly an additional $505 million down the line. With this deal, Seattle-based Kineta, Inc. has certainly received a boost towards its efforts of killing …
Distributed Bio forms multi-target partnership with Good Therapeutics
Distributed Bio, which a global leader in computational optimization of fully human monoclonal antibody libraries, has recently made an announcement confirming a multi-target collaboration with Seattle-based Good Therapeutics Inc. According to BioSpace, Distributed Bio, under the partnership, would be using its SuperHuman antibody library platform …
MIT Engineers claim repurposed wasp venom to cure lung disease
Engineers at the renowned MIT Institute claim to have developed new antimicrobial peptides that fight bacteria causing respiratory diseases and other infections. These antimicrobial peptides are based on a naturally occurring peptide that is produced by the South American wasp. Incidentally, the venom of bees …
Australian researchers claim breakthrough by 10-min cancer test
Ojaswita Kutepatil December 6, 2018
Australian scientists have recently unveiled that they have developed a simple 10-minute blood test that can diagnose cancer anywhere in the human body. Reportedly, the detection process is based on identifying a unique DNA structure that is usually present in all the type of the …
argenx and Cilag GmbH International to collaborate on cancer therapy
argenx SE, a Netherland-based biotechnology firm that develops a large range of differentiated antibody-based therapies for treating severe autoimmune diseases and cancer, has recently inked a deal with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), to develop …
FDA prohibits Coloplast, Boston Scientific from selling surgical mesh
MediciNova plans to move ahead with phase-3 trial of MN-166 in ALS
Page125.org Copyright © 2022.